Merck & Co. Inc., known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for WELIREG® (belzutifan). This marks a significant development as WELIREG becomes the only approved treatment in the United States for adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). These are rare tumors that originate from the same tissue, but differ in their location of formation. The approval is based on data from the LITESPARK-015 clinical trial, highlighting Merck's commitment to providing innovative therapies for patients with rare diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250514679248) on May 14, 2025, and is solely responsible for the information contained therein.